Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?

被引:85
作者
Canedo, J. [1 ]
Lee, S. -H. [1 ]
Pinto, R. [1 ]
Murad-Regadas, S. [1 ]
Rosen, L. [1 ]
Wexner, S. D. [1 ]
机构
[1] Cleveland Clin Florida, Dept Surg, Weston, FL USA
关键词
Resection; Crohn's disease; immunosuppressive; medications; postoperative; infection rates; NECROSIS-FACTOR-ALPHA; ULCERATIVE-COLITIS; INFLIXIMAB; COMPLICATIONS; THERAPY; SAFETY; RISK;
D O I
10.1111/j.1463-1318.2010.02469.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Aim The aim of this study was to analyse postoperative infection in patients undergoing surgery for Crohn's disease (CD) according to the use of preoperative immunosuppressants, including infliximab. Method With IRB approval, the records of all patients with CD who underwent abdominal surgery between 2001 and 2008 were reviewed for comorbidity, preoperative medication, type of surgery, stoma construction and postoperative complications. Patients were divided into three categories according to the preoperative medication within 90 days of surgery as follows: infliximab (IFX), other drugs including steroids and/or immunosuppressive agents (OD) and no drugs (ND). Results Two hundred and twenty-five patients were identified. Preoperative comorbidity, surgical indication and type of surgery were not significantly different among the three groups. Ileocolic resection was the most common procedure [50.8%, IFX group; 61.2%, OD group; 41.3%, ND group (P = 0.09)]. Other procedures included total colectomy (16%), protectomy (15%) and others (18%). Laparoscopic surgery was performed in 47.7%, 45.9% and 29.3% of patients in the IFX, OD and ND groups, respectively (P = 0.04). There were no differences in postoperative rates of infection [pneumonia (P = 0.14), wound infection (P = 0.35), abscess (P = 0.34) or anastomotic leakage (P = 0.44)]. Reoperation was needed in 3.0%, 8.2% and 2.6% of patients in the IFX, OD and ND groups, respectively. Multiple logistic regression found no relationship between infliximab use and infection. Conclusion There was no difference in the rate of postoperative complications among the groups of patients undergoing surgery for CD pretreated with IFX or other immunosuppressive drugs.
引用
收藏
页码:1294 / 1298
页数:5
相关论文
共 15 条
[1]
Timing of surgery in Crohn's disease:: A key issue in the management [J].
Alos, Rafael ;
Hinojosa, Joaquin .
WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (36) :5532-5539
[2]
Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients [J].
Appau, Kweku A. ;
Fazio, Victor W. ;
Shen, Bo ;
Church, James M. ;
Lashner, Bret ;
Remzi, Feza ;
Brzezinski, Aaron ;
Strong, Scott A. ;
Hammel, Jeffrey ;
Kiran, Ravi P. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (10) :1738-1744
[3]
Bednarz W, 2008, HEPATO-GASTROENTEROL, V55, P998
[4]
Safety of biologic therapy [J].
Blonski, Wojciech ;
Lichtenstein, Gary R. .
INFLAMMATORY BOWEL DISEASES, 2007, 13 (06) :769-796
[5]
Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy [J].
Colombel, JF ;
Loftus, EV ;
Tremaine, WJ ;
Pemberton, JH ;
Wolff, BG ;
Young-Fadok, T ;
Harmsen, WS ;
Schleck, CD ;
Sandborn, WJ .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (05) :878-883
[6]
Effect of Perioperative Immunosuppressive Medication on Early Outcome in Crohn's Disease Patients [J].
Indar, Adrian A. ;
Young-Fadok, Tonia M. ;
Heppell, Jacques ;
Efron, Jonathan E. .
WORLD JOURNAL OF SURGERY, 2009, 33 (05) :1049-1052
[7]
Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications [J].
Kunitake, Hiroko ;
Hodin, Richard ;
Shellito, Paul C. ;
Sands, Bruce E. ;
Korzenik, Joshua ;
Bordeianou, Liliana .
JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (10) :1730-1736
[8]
Inhibition of tumor necrosis factor-α attenuates wound breaking strength in rats [J].
Lee, RH ;
Efron, DT ;
Tantry, U ;
Stuelten, C ;
Moldawer, LL ;
Abouhamze, A ;
Barbul, A .
WOUND REPAIR AND REGENERATION, 2000, 8 (06) :547-553
[9]
CROHNS DISEASE (REGIONAL ENTERITIS) OF THE LARGE INTESTINE AND ITS DISTINCTION FROM ULCERATIVE COLITIS [J].
LOCKHARTMUMMERY, HE ;
MORSON, BC .
GUT, 1960, 1 (02) :87-105
[10]
The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study [J].
Marchal, L ;
D'Haens, G ;
Van Assche, G ;
Vermeire, S ;
Noman, M ;
Ferrante, M ;
Hiele, M ;
De Mesquita, MB ;
D'Hoore, A ;
Penninckx, F ;
Rutgeerts, P .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (07) :749-754